April 29th 2025
Among the new data the company plans to show in its presentations is the successful, repeated dosing of an mRNA-LNP in monkeys.
Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.
Should Regulation of Combination Products Become More Centralized in Europe?
May 1st 2013While there are those who want combination products to be controlled by a centralized pharmaceutical-type approval system, the majority of the medical technology industry wants to retain a decentralized device-focused approach.
Astellas and Ambrx Collaborate on Antibody Drug Conjugates for Oncology
April 8th 2013Astellas and Ambrx have entered into a collaboration to discover and develop novel antibody drug conjugates (ADCs) for an undisclosed number of targets in oncology. ADCs enable targeted delivery of drugs to the target tissue.